Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A R Zander

Showing results (201-210 of 225) with videos related to

Pageof 23
Sort By:
Annals of Hematology|March 22, 2002
Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphomaM Hänel, N Kröger, S Sonnenberg, et al.
Bone Marrow Transplantation|June 13, 2000
Roquinimex (Linomide) vs placebo in AML after autologous bone marrow transplantationB Simonsson, T Tötterman, P Hokland, et al.
Klinische Padiatrie|September 23, 1998
[Treatment of hemophagocytic lymphohistiocytosis, HLH, with bone marrow transplantation]M Dürken, E M Schneider, R Blütters-Sawatzki, et al.
Bone Marrow Transplantation|May 12, 2009
Influence of mannose-binding lectin genotypes and serostatus in allo-SCT: analysis of 131 recipients and donorsO W Neth, U Bacher, P Das, et al.
Bone Marrow Transplantation|November 15, 2005
Comparable results in patients with acute lymphoblastic leukemia after related and unrelated stem cell transplantationJ Dahlke, N Kröger, T Zabelina, et al.
Bone Marrow Transplantation|July 9, 2009
Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cellsM Lioznov, J El-Cheikh, F Hoffmann, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 29, 2008
Randomized trial of high-dose adjuvant chemotherapy with autologous hematopoietic stem-cell support versus standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: overall survival after 6 years of follow-upA R Zander, C Schmoor, N Kröger, et al.
Bone Marrow Transplantation|May 25, 1999
Use of a five-agent GVHD prevention regimen in recipients of unrelated donor marrowA R Zander, T Zabelina, N Kröger, et al.
Bone Marrow Transplantation|August 7, 2012
Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patientsN Kröger, T Zabelina, E Klyuchnikov, et al.
Blood|September 1, 1978
Cytogenetic evidence for recurrence of acute myelogenous leukemia after allogeneic bone marrow transplantation in donor hematopoietic cellsG J Elfenbein, D S Brogaonkar, W B Bias, et al.
Pageof 23

Showing results (201-210 of 225) with videos related to

Sort By:
Pageof 23
Annals of Hematology|March 22, 2002
Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphomaM Hänel, N Kröger, S Sonnenberg, et al.
Bone Marrow Transplantation|June 13, 2000
Roquinimex (Linomide) vs placebo in AML after autologous bone marrow transplantationB Simonsson, T Tötterman, P Hokland, et al.
Klinische Padiatrie|September 23, 1998
[Treatment of hemophagocytic lymphohistiocytosis, HLH, with bone marrow transplantation]M Dürken, E M Schneider, R Blütters-Sawatzki, et al.
Bone Marrow Transplantation|May 12, 2009
Influence of mannose-binding lectin genotypes and serostatus in allo-SCT: analysis of 131 recipients and donorsO W Neth, U Bacher, P Das, et al.
Bone Marrow Transplantation|November 15, 2005
Comparable results in patients with acute lymphoblastic leukemia after related and unrelated stem cell transplantationJ Dahlke, N Kröger, T Zabelina, et al.
Bone Marrow Transplantation|July 9, 2009
Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cellsM Lioznov, J El-Cheikh, F Hoffmann, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 29, 2008
Randomized trial of high-dose adjuvant chemotherapy with autologous hematopoietic stem-cell support versus standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: overall survival after 6 years of follow-upA R Zander, C Schmoor, N Kröger, et al.
Bone Marrow Transplantation|May 25, 1999
Use of a five-agent GVHD prevention regimen in recipients of unrelated donor marrowA R Zander, T Zabelina, N Kröger, et al.
Bone Marrow Transplantation|August 7, 2012
Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patientsN Kröger, T Zabelina, E Klyuchnikov, et al.
Blood|September 1, 1978
Cytogenetic evidence for recurrence of acute myelogenous leukemia after allogeneic bone marrow transplantation in donor hematopoietic cellsG J Elfenbein, D S Brogaonkar, W B Bias, et al.
Pageof 23